Reuters logo
BRIEF-Successful CANTOS Inflammation Trial supports rationale for Resverlogix' ongoing betonmace trial
2017年8月29日 / 晚上7点50分 / 3 个月前

BRIEF-Successful CANTOS Inflammation Trial supports rationale for Resverlogix' ongoing betonmace trial

Aug 29 (Reuters) - Resverlogix Corp

* under CANTOS trial treatment with Resverlogix’ apabetalone has demonstrated a reduction in inflammatory mediator il-6 by 29 percent​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below